
MAZE Stock Forecast & Price Target
MAZE Analyst Ratings
Bulls say
Maze Therapeutics is an attractive investment due to their promising drug MZE829 that could potentially delay disease progression and reverse symptoms of chronic kidney disease and other conditions by inhibiting APOL1 pore formation and function. With potential accelerated approval and the ability to slow the progression of diabetes, there are strong financial prospects for the company. However, there may be concerns regarding competition and effectiveness, as well as a need for further research and genotyping to fully understand the impacts of the drug on individuals with chronic kidney disease.
Bears say
Maze Therapeutics is a clinical-stage biopharmaceutical company that is utilizing its Compass platform to develop precision medicines for renal, cardiovascular, and related metabolic diseases. However, their lead candidate MZE829 has a dual mechanism of action (disrupting pore assembly and blocking function) and targets the EC90 threshold, suggesting a higher ceiling for efficacy. While competition in the APOL1-mediated kidney disease market is increasing, Maze's rigorous PK/PD strategy and expansion beyond FSGS to include diabetic kidney disease and hypertensive CKD potentially positions them to capture a significant share of the market. However, time and the HORIZON trial will be the true test of MZE829's efficacy and potential "best-in-class" profile.
This aggregate rating is based on analysts' research of Maze Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
MAZE Analyst Forecast & Price Prediction
Start investing in MAZE
Order type
Buy in
Order amount
Est. shares
0 shares